Last update at 2025-07-10T17:20:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results
Wed 21 May 25, 08:30 PMBausch + Lomb Launches Zenlens® CHROMA HOA™ in the United States
Wed 14 May 25, 10:59 AMBausch + Lomb Announces First-Quarter 2025 Results
Wed 30 Apr 25, 10:57 AMBausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall
Thu 24 Apr 25, 11:00 AM3 Reasons to Sell BLCO and 1 Stock to Buy Instead
Fri 18 Apr 25, 09:16 AMMag 7 slide, gold rises, Bausch + Lomb recall: Market Minute
Fri 28 Mar 25, 05:33 PMWhy Bausch + Lomb (BLCO) Shares Are Plunging Today
Fri 28 Mar 25, 05:20 PMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 73.00M | 318.00M | 290.00M | 399.00M | 417.00M |
Minority interest | -9.00000M | -11.00000M | -1.00000M | -5.00000M | - |
Net income | 15.00M | 182.00M | -17.00000M | 298.00M | 710.00M |
Selling general administrative | 1478.00M | 1389.00M | 1253.00M | 1382.00M | - |
Selling and marketing expenses | - | - | - | - | - |
Gross profit | 2249.00M | 2298.00M | 2127.00M | 2451.00M | 2352.00M |
Reconciled depreciation | 244.00M | 415.00M | 442.00M | 469.00M | - |
Ebit | 207.00M | 329.00M | 260.00M | 532.00M | 416.00M |
Ebitda | 457.00M | 785.00M | 750.00M | 1001.00M | 932.00M |
Depreciation and amortization | 250.00M | 456.00M | 490.00M | 469.00M | 516.00M |
Non operating income net other | - | - | - | - | - |
Operating income | 207.00M | 329.00M | 260.00M | 532.00M | 416.00M |
Other operating expenses | 3548.00M | 3419.00M | 3114.00M | 3315.00M | 3238.00M |
Interest expense | 146.00M | 63.00M | 19.00M | 138.00M | 29.00M |
Tax provision | 58.00M | 125.00M | 307.00M | 96.00M | - |
Interest income | 6.00M | 0.00000M | 3.00M | 1.00M | - |
Net interest income | -140.00000M | 0.00000M | 3.00M | 1.00M | - |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 58.00M | 125.00M | 307.00M | 96.00M | -302.00000M |
Total revenue | 3768.00M | 3765.00M | 3412.00M | 3778.00M | 3665.00M |
Total operating expenses | 2029.00M | 1952.00M | 1829.00M | 1988.00M | 1925.00M |
Cost of revenue | 1519.00M | 1467.00M | 1285.00M | 1327.00M | 1313.00M |
Total other income expense net | -134.00000M | -11.00000M | 30.00M | -133.00000M | 1.00M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 15.00M | 193.00M | -17.00000M | 303.00M | - |
Net income applicable to common shares | 6.00M | 182.00M | -18.00000M | 298.00M | - |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
Total assets | 13469.00M | 13442.00M | 11144.00M | 10823.00M | 11266.00M |
Intangible assets | 3494.00M | 3589.00M | 2058.00M | 2264.00M | 2562.00M |
Earning assets | - | - | - | - | - |
Other current assets | 410.00M | 541.00M | 431.00M | 168.00M | 155.00M |
Total liab | 6925.00M | 6522.00M | 4043.00M | 1421.00M | 1278.00M |
Total stockholder equity | 6473.00M | 6850.00M | 7033.00M | 9329.00M | 9918.00M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 403.00M | 400.00M | 901.00M | 860.00M | 731.00M |
Common stock | - | - | - | 10364.00M | 10807.00M |
Capital stock | 0.00000M | 0.00000M | 0.00000M | 10364.00M | 10807.00M |
Retained earnings | -571.00000M | -254.00000M | 6.00M | - | - |
Other liab | - | - | 244.00M | 230.00M | 286.00M |
Good will | 4523.00M | 4575.00M | 4507.00M | 4586.00M | 4685.00M |
Other assets | - | - | 1023.00M | 1001.00M | 1101.00M |
Cash | 305.00M | 331.00M | 354.00M | 174.00M | 238.00M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 1738.00M | 1579.00M | 1296.00M | 1099.00M | 909.00M |
Current deferred revenue | - | 627.00M | - | - | - |
Net debt | 4479.00M | 4231.00M | 2082.00M | -174.00000M | -238.00000M |
Short term debt | - | 30.00M | 25.00M | - | - |
Short long term debt | 40.00M | 30.00M | 25.00M | - | - |
Short long term debt total | - | 4562.00M | 2436.00M | - | - |
Other stockholder equity | - | 8349.00M | 8285.00M | -1035.00000M | -889.00000M |
Property plant equipment | - | - | 1419.00M | 1337.00M | 1264.00M |
Total current assets | 2788.00M | 2742.00M | 2137.00M | 1635.00M | 1654.00M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | - | 468.00M | 2479.00M | 2671.00M |
Short term investments | - | - | - | - | - |
Net receivables | 1026.00M | 839.00M | 724.00M | 721.00M | 645.00M |
Long term debt | 4744.00M | 4532.00M | 2411.00M | - | - |
Inventory | 1036.00M | 1028.00M | 628.00M | 572.00M | 616.00M |
Accounts payable | 389.00M | 522.00M | 370.00M | 239.00M | 178.00M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | - | -1245.00000M | -1258.00000M | -1035.00000M | -889.00000M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | - |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 294.00M | 225.00M | 215.00M | 180.00M | 165.00M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 10681.00M | 10700.00M | 9007.00M | 9188.00M | 9612.00M |
Capital lease obligations | - | - | - | - | - |
Long term debt total | - | - | - | - | - |
Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Investments | -215.00000M | -214.00000M | -256.00000M | -186.00000M | - |
Change to liabilities | 189.00M | 163.00M | -144.00000M | 78.00M | - |
Total cashflows from investing activities | -215.00000M | -214.00000M | -256.00000M | -186.00000M | - |
Net borrowings | 2458.00M | 28.00M | 28.00M | 28.00M | - |
Total cash from financing activities | 81.00M | -712.00000M | -232.00000M | -606.00000M | -665.00000M |
Change to operating activities | -7.00000M | -13.00000M | 40.00M | -6.00000M | - |
Net income | 15.00M | 193.00M | -17.00000M | 303.00M | 719.00M |
Change in cash | 203.00M | -61.00000M | 46.00M | 4.00M | 16.00M |
Begin period cash flow | 177.00M | 238.00M | 192.00M | 188.00M | 172.00M |
End period cash flow | 380.00M | 177.00M | 238.00M | 192.00M | 188.00M |
Total cash from operating activities | 345.00M | 873.00M | 522.00M | 799.00M | 763.00M |
Issuance of capital stock | - | - | - | - | - |
Depreciation | 379.00M | 415.00M | 442.00M | 469.00M | 495.00M |
Other cashflows from investing activities | - | - | - | - | - |
Dividends paid | - | - | - | - | - |
Change to inventory | -106.00000M | -15.00000M | -32.00000M | -91.00000M | -7.00000M |
Change to account receivables | -95.00000M | -107.00000M | 77.00M | -21.00000M | -9.00000M |
Sale purchase of stock | - | - | - | - | - |
Other cashflows from financing activities | 94.00M | -712.00000M | -232.00000M | -606.00000M | -665.00000M |
Change to netincome | -21.00000M | 248.00M | 157.00M | 72.00M | - |
Capital expenditures | 175.00M | 209.00M | 259.00M | 180.00M | 101.00M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | -19.00000M | 28.00M | -59.00000M | -40.00000M | -78.00000M |
Stock based compensation | 62.00M | 62.00M | 50.00M | 50.00M | 43.00M |
Other non cash items | -2.00000M | 59.00M | 9.00M | 56.00M | 28.00M |
Free cash flow | 170.00M | 664.00M | 263.00M | 619.00M | 662.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
BLCO Bausch + Lomb Corp |
0.27 1.40% | 19.56 | - | 21.98 | 1.21 | 0.67 | 1.84 | 17.69 |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4
Name | Title | Year Born |
---|---|---|
Mr. Joseph C. Papa | CEO & Director | 1956 |
Mr. Osama A. Eldessouky | Exec. VP & CFO | 1972 |
Ms. Christina M. Ackermann | Exec. VP, Gen. Counsel & Pres of Ophthalmic Pharmaceuticals | 1965 |
Mr. Joseph F. Gordon | Pres of Global Consumer, Surgical & Vision Care | 1965 |
Ms. Kelly Webber | Exec. VP & Chief HR Officer | NA |
Dr. Yehia Hashad M.D. | Exec. VP of R&D and Chief Medical officer | 1967 |
Mr. Louis W. Yu | Exec. VP & Chief Quality Officer | 1950 |
Mr. Dennis Asharin | Exec. VP and Chief Global Manufacturing & Supply Chain Officer | NA |
Mr. Brenton L. Saunders J.D. | CEO & Chairman | 1970 |
Mr. Osama A. Eldessouky | Executive VP & CFO | 1972 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.